Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report

Abstract

A 72‐year‐old man, diagnosed with advanced lung squamous cell carcinoma, was administered of cisplatin plus gemcitabine with necitumumab, a human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), as a sixth‐line treatment. Tumor shrinkage was observed, but asymptomatic grade 4 hypomagnesemia occurred on day 8 of the second cycle. He received magnesium replenishment and hypomagnesemia recovered on day 40, but tumor progression was observed during the period of magnesium correction. Hypomagnesemia is known as a major adverse event of treatment with anti‐EGFR antibodies, but there have been no case reports of severe hypomagnesemia or its clinical course.

Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review

“…On the eighth day of the second cycle, severe hypomagnesemia occurred, one of the documented adverse effects of monoclonal antibodies. 70 …”

“…In the sixth line of treatment, cisplatin and gemcitabine combined with Necitumumab were used. On the eighth day of the second cycle, severe hypomagnesemia occurred, one of the documented adverse effects of monoclonal antibodies 70 …”